Literature DB >> 16634801

Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice.

B Sheil1, J MacSharry, L O'Callaghan, A O'Riordan, A Waters, J Morgan, J K Collins, L O'Mahony, F Shanahan.   

Abstract

While the impact of Bifidobacterium infantis 35624 and other probiotics on cytokines has been shown in established colitis, the effects of B. infantis consumption in pre-inflammation of interleukin (IL)-10 knock-out (KO) mice and on the wild-type (WT) C57Bl/6 mice have not been well demonstrated. The objective of this study was to examine cytokine responses in mucosal and systemic lymphoid compartments of IL-10 KO mice early in disease and to compare with control WT mice. Mice were fed B. infantis or placebo for 5 weeks and culled prior to the onset of chronic intestinal inflammation (12-14 weeks). The spleen, Peyer's patches and intestinal mucosa were removed and stimulated with various bacterial stimuli. Cytokine levels were measured by enzyme-linked immunosorbent assay. While basal intestinal and systemic cytokine profiles of WT and IL-10 KO mice were similar, transforming growth factor (TGF)-beta was reduced in the spleen of IL-10 KO mice. Following probiotic consumption, interferon (IFN)-gamma was reduced in the Peyer's patch of both WT and IL-10 KO mice. Alterations in IFN-gamma in the Peyer's patches of WT mice (enhancement) versus IL-10 KO (reduction) were observed following in vitro stimulation with salmonella. Differential IL-12p40, CCL2 and CCL5 responses were also observed in IL-10 KO mice and WT mice. The cytokine profile of IL-10 KO mice in early disease was similar to that of WT mice. The most pronounced changes occurred in the Peyer's patch of IL-10 KO mice, suggesting a probiotic mechanism of action independent of IL-10. This study provides a rationale for the use of B. infantis 35624 for the treatment of gastrointestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16634801      PMCID: PMC1809667          DOI: 10.1111/j.1365-2249.2006.03051.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  46 in total

1.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.

Authors:  P Gionchetti; F Rizzello; A Venturi; P Brigidi; D Matteuzzi; G Bazzocchi; G Poggioli; M Miglioli; M Campieri
Journal:  Gastroenterology       Date:  2000-08       Impact factor: 22.682

Review 2.  Probiotics in inflammatory bowel disease--therapeutic rationale and role.

Authors:  Fergus Shanahan
Journal:  Adv Drug Deliv Rev       Date:  2004-04-19       Impact factor: 15.470

3.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function.

Authors:  K Madsen; A Cornish; P Soper; C McKaigney; H Jijon; C Yachimec; J Doyle; L Jewell; C De Simone
Journal:  Gastroenterology       Date:  2001-09       Impact factor: 22.682

Review 4.  Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation.

Authors:  D M Rennick; M M Fort
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

5.  Targeting enteric bacteria in treatment of inflammatory bowel diseases: why, how, and when.

Authors:  R Balfour Sartor
Journal:  Curr Opin Gastroenterol       Date:  2003-07       Impact factor: 3.287

6.  Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial.

Authors:  Paolo Gionchetti; Fernando Rizzello; Ulf Helwig; Alessandro Venturi; Karen Manon Lammers; Patrizia Brigidi; Beatrice Vitali; Gilberto Poggioli; Mario Miglioli; Massimo Campieri
Journal:  Gastroenterology       Date:  2003-05       Impact factor: 22.682

7.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

8.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines.

Authors:  L A Dieleman; M J Palmen; H Akol; E Bloemena; A S Peña; S G Meuwissen; E P Van Rees
Journal:  Clin Exp Immunol       Date:  1998-12       Impact factor: 4.330

9.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD)

Authors:  R Duchmann; I Kaiser; E Hermann; W Mayet; K Ewe; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

10.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  22 in total

Review 1.  The Microbiome in Visceral Medicine: Inflammatory Bowel Disease, Obesity and Beyond.

Authors:  Mircea T Chiriac; Mousumi Mahapatro; Markus F Neurath; Christoph Becker
Journal:  Visc Med       Date:  2017-04-07

2.  Bifidobacteria isolated from infants and cultured on human milk oligosaccharides affect intestinal epithelial function.

Authors:  Maciej Chichlowski; Guillaume De Lartigue; J Bruce German; Helen E Raybould; David A Mills
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-09       Impact factor: 2.839

Review 3.  Differential Establishment of Bifidobacteria in the Breastfed Infant Gut.

Authors:  Zachery T Lewis; David A Mills
Journal:  Nestle Nutr Inst Workshop Ser       Date:  2017-03-27

4.  Functional analysis of D-alanylation of lipoteichoic acid in the probiotic strain Lactobacillus rhamnosus GG.

Authors:  Mónica Perea Vélez; Tine L A Verhoeven; Christian Draing; Sonja Von Aulock; Markus Pfitzenmaier; Armin Geyer; Ivo Lambrichts; Corinne Grangette; Bruno Pot; Jos Vanderleyden; Sigrid C J De Keersmaecker
Journal:  Appl Environ Microbiol       Date:  2007-04-13       Impact factor: 4.792

5.  Probiotics: from bench to market.

Authors:  Marguerite Klein; Mary Ellen Sanders; Tri Duong; Howard A Young
Journal:  Ann N Y Acad Sci       Date:  2010-11       Impact factor: 5.691

6.  Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice.

Authors:  James P Moran; Jens Walter; Gerald W Tannock; Susan L Tonkonogy; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

7.  Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease.

Authors:  Linda M Feighery; Philip Smith; Liam O'Mahony; Padraic G Fallon; David J Brayden
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

8.  Bifidobacterium infantis 35624 protects against salmonella-induced reductions in digestive enzyme activity in mice by attenuation of the host inflammatory response.

Authors:  Erin L Symonds; Caitlin O'Mahony; Susan Lapthorne; David O'Mahony; John Mac Sharry; Liam O'Mahony; Fergus Shanahan
Journal:  Clin Transl Gastroenterol       Date:  2012-05-10       Impact factor: 4.488

9.  The effect of dietary prebiotics and probiotics on body weight, large intestine indices, and fecal bile acid profile in wild type and IL10-/- mice.

Authors:  Shiu-Ming Kuo; Patricia M Merhige; Lee R Hagey
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

10.  Immune disorders and its correlation with gut microbiome.

Authors:  Ji-Sun Hwang; Chang-Rok Im; Sin-Hyeog Im
Journal:  Immune Netw       Date:  2012-08-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.